Asymmetric Total Syntheses of Di‐ and Sesquiterpenoids by Catalytic C−C Activation of Cyclopentanones
To show the synthetic utility of the catalytic C−C activation of less strained substrates, described here are the collective and concise syntheses of the natural products (−)‐microthecaline A, (−)‐leubehanol, (+)‐pseudopteroxazole, (+)‐seco‐pseudopteroxazole, pseudopterosin A–F and G—J aglycones, an...
Saved in:
Published in | Angewandte Chemie Vol. 132; no. 20; pp. 7922 - 7930 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Weinheim
Wiley Subscription Services, Inc
11.05.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | To show the synthetic utility of the catalytic C−C activation of less strained substrates, described here are the collective and concise syntheses of the natural products (−)‐microthecaline A, (−)‐leubehanol, (+)‐pseudopteroxazole, (+)‐seco‐pseudopteroxazole, pseudopterosin A–F and G—J aglycones, and (+)‐heritonin. The key step in these syntheses involve a Rh‐catalyzed C−C/C−H activation cascade of 3‐arylcyclopentanones, which provides a rapid and enantioselective route to access the polysubstituted tetrahydronaphthalene cores presented in these natural products. Other important features include 1) the direct C−H amination of the tetralone substrate in the synthesis of (−)‐microthecaline A, 2) the use of phosphoric acid to enhance efficiency and regioselectivity for problematic cyclopentanone substrates in the C−C activation reactions, and 3) the direct conversion of serrulatane into amphilectane diterpenes by an allylic cyclodehydrogenation coupling.
Zur Demonstration des Nutzens der Rh‐katalysierten C‐C/C‐H‐Aktivierungskaskade von 3‐Arylcyclopentanonen für die Synthese werden die kollektiven knappen und asymmetrischen, vier‐ bis neunstufigen Synthesen folgender Terpenoide beschrieben: (−)‐Microthecalin A, (−)‐Leubehanol, (+)‐Pseudopteroxazol, (+)‐seco‐Pseudopteroxazol, Pseudopterosin‐A–F‐ und Pseudopterosin‐G–J‐Aglycone sowie (+)‐Heritonin. |
---|---|
ISSN: | 0044-8249 1521-3757 |
DOI: | 10.1002/ange.201915821 |